Innate Pharma reports Full Year 2022 Financial Results and Business Update
Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2...Number of shares and voting rights of Innate Pharma as of March 1, 2023
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma announces conference call and webcast for Full Year 2022 financial results
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT...Innate Pharma provides update on Silicon Valley Bank exposure
Innate Pharma does not have any financial exposure to Silicon Valley Bank Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has learned that Silicon Valley Bank has been...Number of shares and voting rights of Innate Pharma as of February 1, 2023
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming...Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. Innate...Innate Pharma announces publication of preclinical data with a trifunctional NK cell engager in acute myeloid leukemia in Nature Biotechnology
Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by...Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Sanofi gains exclusive license to Innate’s B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022
Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKETTM (Antibody...
